Advances in Antibacterial Therapy Against Emerging Bacterial Pathogens

Seminars in Hematology

Volumn 46, Issue 3, 2009, Pages 198-211

  Pournaras, Spyros ^a   Iosifidis, Elias ^b   Roilides, Emmanuel ^b  

^a UNIVERSITY OF THESSALY   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COLISTIMETHATE; COLISTIN; DALBAVANCIN; DAPTOMYCIN; DORIPENEM; FROPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; NAFCILLIN; ORITAVANCIN; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TELAVANCIN; TIGECYCLINE; TIMENTIN; TOMOPENEM; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRONCHOSPASM; CATHETER INFECTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; CONTINUOUS INFUSION; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG PENETRATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ENTEROCOCCAL INFECTION; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL INFECTION; HUMAN; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INFECTION CONTROL; LACTIC ACIDOSIS; MAXIMUM PLASMA CONCENTRATION; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; MUSCLE DISEASE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OPTIC NERVE DISEASE; OPTIC NEURITIS; PARESTHESIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; SEROTONIN SYNDROME; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA; VOMITING;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COMMUNICABLE DISEASES, EMERGING; CROSS INFECTION; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HEMATOLOGIC DISEASES; HUMANS; IMMUNOCOMPROMISED HOST;

EID: 67249101200     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2009.03.007     Document Type: Article

References (116)

1. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 6th ed. (2006), CLSI, Villanova, PA CLSI approved standard M7-A7
2. Ikonomidis A., Michail G., Vasdeki A., Labrou M., Karavasilis V., Stathopoulos C., et al. In vitro and in vivo evaluations of oxacillin efficiency against mecA-positive oxacillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 52 (2008) 3905-3908
3. Chambers H.F., and Sachdeva M. Binding of beta-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus. J Infect Dis 161 (1990) 1170-1176
4. Duckworth G.J., Lothian J.L., and Williams J.D. Methicillin-resistant Staphylococcus aureus: report of an outbreak in a London teaching hospital. J Hosp Infect 11 (1988) 1-15
5. Grundmann H., Aires-de-Sousa M., Boyce J., and Tiemersma E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 368 (2006) 874-885
6. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32 (2004) 470-485
7. Boucher H.W., and Corey G.R. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 46 Suppl 5 (2008) S344-S349
8. Pournaras S., Slavakis A., Polyzou A., Sofianou D., Maniatis A.N., and Tsakris A. Nosocomial spread of an unusual methicillin-resistant Staphylococcus aureus clone that is sensitive to all non-β-lactam antibiotics, including tobramycin. J Clin Microbiol 39 (2001) 779-781
9. Nygaard T.K., DeLeo F.R., and Voyich J.M. Community-associated methicillin-resistant Staphylococcus aureus skin infections: advances toward identifying the key virulence factors. Curr Opin Infect Dis 21 (2008) 147-152
10. Diep B.A., Chambers H.F., Graber C.J., Szumowski J.D., Miller L.G., Han L.L., et al. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med 148 (2008) 249-257
11. Cosgrove S.E., Carroll K.C., and Perl T.M. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 39 (2004) 539-545
12. Appelbaum P.C. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 12 Suppl 1 (2006) 16-23
13. Sung J.M., and Lindsay J.A. Staphylococcus aureus strains that are hypersusceptible to resistance gene transfer from enterococci. Antimicrob Agents Chemother 51 (2007) 2189-2191
14. Tiwari H.K., and Sen M.R. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infect Dis 6 (2006) 156
15. Papanicolaou G.A., Meyers B.R., Meyers J., Mendelson M.H., Lou W., Emre S., et al. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis 23 (1996) 760-766
16. Matar M.J., Tarrand J., Raad I., and Rolston K.V. Colonization and infection with vancomycin-resistant Enterococcus among patients with cancer. Am J Infect Control 34 (2006) 534-536
17. Sahm D.F., Marsilio M.K., and Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database-USA. Clin Infect Dis 29 (1999) 259-263
18. Pournaras S., Malamou-Lada H., Maniati M., Mylona-Petropoulou D., Vagiakou-Voudris H., Tsakris A., et al. Persistence of a clone of glycopeptide-resistant Enterococcus faecalis among patients in an intensive care unit of a Greek hospital. J Antimicrob Chemother 53 (2004) 109-112
19. Hayden M.K. Insights into the epidemiology and control of infection with vancomycin-resistant enterococci. Clin Infect Dis 31 (2000) 1058-1065
20. Maniatis A.N., Pournaras S., Kanellopoulou M., Kontos F., Dimitroulia E., Papafrangas E., et al. Dissemination of clonally unrelated erythromycin- and glycopeptide-resistant Enterococcus faecium isolates in a tertiary Greek hospital. J Clin Microbiol 39 (2001) 4571-4574
21. Donskey C.J., Schreiber J.R., Jacobs M.R., Shekar R., Salata R.A., Gordon S., et al. A polyclonal outbreak of predominantly VanB vancomycin-resistant enterococci in northeast Ohio. Northeast Ohio Vancomycin-Resistant Enterococcus Surveillance Program. Clin Infect Dis 29 (1999) 573-579
22. Leavis H.L., Willems R.J., Top J., Spalburg E., Mascini E.M., Fluit A.C., et al. Epidemic and nonepidemic multidrug-resistant Enterococcus faecium. Emerg Infect Dis 9 (2003) 1108-1115
23. Scheetz M.H., Knechtel S.A., Malczynski M., Postelnick M.J., and Qi C. Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption. Antimicrob Agents Chemother 52 (2008) 2256-2259
24. DiazGranados C.A., and Jernigan J.A. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis 191 (2005) 588-595
25. Paterson D.L., and Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18 (2005) 657-686
26. Canton R., and Coque T.M. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol 9 (2006) 466-475
27. Queenan A.M., and Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 20 (2007) 440-458
28. Rossolini G.M., Luzzaro F., Migliavacca R., Mugnaioli C., Pini B., De Luca F., et al. First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. Antimicrob Agents Chemother 52 (2008) 4023-4029
29. Navon-Venezia S., Chmelnitsky I., Leavitt A., Schwaber M.J., Schwartz D., and Carmeli Y. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother 50 (2006) 3098-3101
30. Tsakris A., Kristo I., Poulou A., Themeli-Digalaki K., Ikonomidis A., Petropoulou D., et al. Evaluation of boronic acid disk tests for differentiating KPC-possessing Klebsiella pneumoniae isolates in the clinical laboratory. J Clin Microbiol (2008) PMID:19073868
31. CLSI document. 2007. Clinical and laboratory standard methods. Performance standards for antimicrobial susceptibility testing: seventeenth informational supplement (2007), Clinical and Laboratory Standard Institute, Wayne, PA M100-S17
32. Paterson D.L., Ko W.C., Von Gottberg A., Casellas J.M., Mulazimoglu L., Klugman K.P., et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 39 (2001) 2206-2212
33. Tsakris A., Pournaras S., Woodford N., Palepou M.F., Babini G.S., Douboyas J., et al. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol 38 (2000) 1290-1292
34. Livermore D.M. Of pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 47 (2001) 247-250
35. Lee N.Y., Lee H.C., Ko N.Y., Chang C.M., Shih H.I., Wu C.J., et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 28 (2007) 713-719
36. Chan P.C., Huang L.M., Lin H.C., Chang L.Y., Chen M.L., Lu C.Y., et al. Control of an outbreak of pandrug-resistant Acinetobacter baumannii colonization and infection in a neonatal intensive care unit. Infect Control Hosp Epidemiol 28 (2007) 423-429
37. Go E.S., Urban C., Burns J., Kreiswirth B., Eisner W., Mariano N., et al. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 344 (1994) 1329-1332
38. Li J., Rayner C.R., Nation R.L., Owen R.J., Spelman D., Tan K.E., et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50 (2006) 2946-2950
39. Navon-Venezia S., Leavitt A., and Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 59 (2007) 772-774
40. Sung J.Y., Kwon K.C., Park J.W., Kim Y.S., Kim J.M., Shin K.S., et al. Dissemination of IMP-1 and OXA type beta-lactamase in carbapenem-resistant Acinetobacter baumannii. Korean J Lab Med 28 (2008) 16-23
41. Ikonomidis A., Ntokou E., Maniatis A.N., Tsakris A., and Pournaras S. Hidden VIM-1 metallo-beta-lactamase phenotypes among Acinetobacter baumannii clinical isolates. J Clin Microbiol 46 (2008) 346-349
42. Mendes R.E., Bell J.M., Turnidge J.D., Castanheira M., and Jones R.N. Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. J Antimicrob Chemother 63 (2009) 55-59
43. Manfredi R. Update on the appropriate use of linezolid in clinical practice. Therapeut Clin Risk Manage 2 (2006) 455-464
44. Eliopoulos G.M. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 36 (2003) 473-481
45. Falagas M.E., Siempos I.I., and Vardakas K.Z. Linezolid versus glycopeptide or beta-lactam for treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 8 (2008) 53-66
46. Falagas M.E., Manta K.G., Ntziora F., and Vardakas K.Z. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 58 (2006) 273-280
47. Ntziora F., and Falagas M.E. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother 41 (2007) 296-308
48. Gerson S.L., Kaplan S.L., Bruss J.B., Le V., Arellano F.M., Hafkin B., et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 46 (2002) 2723-2726
49. Taylor J.J., Wilson J.W., and Estes L.L. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis 43 (2006) 180-187
50. Smith P.F., Birmingham M.C., Noskin G.A., Meagher A.K., Forrest A., Rayner C.R., et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant gram-positive infections in cancer patients with neutropenia. Ann Oncol 14 (2003) 795-801
51. Jaksic B., Martinelli G., Perez-Oteyza J., Hartman C.S., Leonard L.B., and Tack K.J. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 42 (2006) 597-607
52. Tattevin P., and Camus C. What can we learn from studies comparing linezolid with vancomycin in neutropenic patients when vancomycin dosages are not optimized?. Clin Infect Dis 42 (2006) 1813-1814
53. Muthaiyan A., Silverman J.A., Jayaswal R.K., and Wilkinson B.J. Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization. Antimicrob Agents Chemother 52 (2008) 980-990
54. Hawkey P.M. Pre-clinical experience with daptomycin. J Antimicrob Chemother 62 Suppl 3 (2008) iii7-iii14
55. Poutsiaka D.D., Skiffington S., Miller K.B., Hadley S., and Snydman D.R. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 54 (2007) 567-571
56. Sakoulas G., Golan Y., Lamp K.C., Friedrich L.V., and Russo R. Daptomycin in the treatment of bacteremia. Am J Med 120 10 Suppl 1 (2007) S21-S27
57. Lalani T., Boucher H.W., Cosgrove S.E., Fowler V.G., Kanafani Z.A., Vigliani G.A., et al. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. J Antimicrob Chemother 61 (2008) 177-182
58. Silverman J.A., Mortin L.I., Vanpraagh A.D., Li T., and Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191 (2005) 2149-2152
59. Pertel P.E., Bernardo P., Fogarty C., Matthews P., Northland R., Benvenuto M., et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 46 (2008) 1142-1151
60. Falagas M.E., Giannopoulou K.P., Ntziora F., and Vardakas K.Z. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother 60 (2007) 7-19
61. Fowler Jr. V.G., Boucher H.W., Corey G.R., Abrutyn E., Karchmer A.W., Rupp M.E., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355 (2006) 653-665
62. Mangili A., Bica I., Snydman D.R., and Hamer D.H. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 40 (2005) 1058-1060
63. Cui L., Tominaga E., Neoh H.M., and Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 50 (2006) 1079-1082
64. Sakoulas G., Alder J., Thauvin-Eliopoulos C., Moellering Jr. R.C., and Eliopoulos G.M. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 50 (2006) 1581-1585
65. Linden P.K. Vancomycin resistance: are there better glycopeptides coming?. Exp Rev Antiinfect Ther 6 (2008) 917-928
66. Laohavaleeson S., Kuti J.L., and Nicolau D.P. Telavancin: a novel lipoglycopeptide for serious gram-positive infections. Exp Opin Invest Drugs 16 (2007) 347-357
67. Hegde S., Skinner R., Difuntorum S., and Krause K. Efficacy of telavancin against hVISA infections in the neutropenic murine bacteremia model. [abstract B-1012]. 48th Annual Interscience Conference on Antimicrobial Agents and hemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting; Washington, DC (2008)
68. Nannini E.C., and Stryjewski M.E. A new lipoglycopeptide: telavancin. Exp Opin Pharmacother 9 (2008) 2197-2207
69. Stryjewski M.E., Graham D.R., Wilson S.E., O'Riordan W., Young D., Lentnek A., et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 46 (2008) 1683-1693
70. Kim S.J., Cegelski L., Stueber D., Singh M., Dietrich E., Tanaka K.S., et al. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J Mol Biol 377 (2008) 281-293
71. Poulakou G., and Giamarellou H. Oritavancin: a new promising agent in the treatment of infections due to gram-positive pathogens. Exp Opin Invest Drugs 17 (2008) 225-243
72. Crandon J., and Nicolau D.P. Oritavancin: a potential weapon in the battle against serious gram-positive pathogens. Future Microbiol 3 (2008) 251-263
73. Hartman C.S., Wasilewski M.M., and Bates B.M. Oritavancin in the treatment of complicated skin and skin structure infections (cSSSI): combined results of two phase 3 multinational trials. [abstract L 1514]. 48th Annual Interscience Conference on Antimicrobial Agents and hemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting; Washington, DC (2008)
74. Bennett J.W., Lewis J.S., and Ellis M.W. Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review. Therapeut Clin Risk Manage 4 (2008) 31-40
75. Poulakou G., and Giamarellou H. Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant gram-negative pathogens. Exp Opin Invest Drugs 17 (2008) 749-771
76. Kattan J.N., Villegas M.V., and Quinn J.P. New developments in carbapenems. Clin Microbiol Infect 14 (2008) 1102-1111
77. Gettig J.P., Crank C.W., and Philbrick A.H. Faropenem medoxomil. Ann Pharmacother 42 (2008) 80-90
78. Koga T., Masuda N., Kakuta M., Namba E., Sugihara C., and Fukuoka T. Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother 52 (2008) 2849-2854
79. Pliatsika V., Afkou Z., Protonotariou E., and Sofianou D. In vitro activity of tigecycline against metallo-beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 60 (2007) 1406-1407
80. Jones C.H., Tuckman M., Howe A.Y., Orlowski M., Mullen S., Chan K., et al. Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections. Antimicrob Agents Chemother 50 (2006) 505-510
81. Noviello S., Ianniello F., Leone S., Fiore M., and Esposito S. In vitro activity of tigecycline: MICs, MBCs, time-kill curves and post-antibiotic effect. J Chemother (Florence, Italy) 20 (2008) 577-580
82. Rodvold K.A., Gotfried M.H., Cwik M., Korth-Bradley J.M., Dukart G., and Ellis-Grosse E.J. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 58 (2006) 1221-1229
83. Stein G.E., and Craig W.A. Tigecycline: a critical analysis. Clin Infect Dis 43 (2006) 518-524
84. Conte Jr. J.E., Golden J.A., Kelly M.G., and Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 25 (2005) 523-529
85. Karageorgopoulos D.E., Kelesidis T., Kelesidis I., and Falagas M.E. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 62 (2008) 45-55
86. Babinchak T., Ellis-Grosse E., Dartois N., Rose G.M., and Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 41 Suppl 5 (2005) S354-S367
87. Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G., and Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41 Suppl 5 (2005) S341-S353
88. Tanaseanu C., Bergallo C., Teglia O., Jasovich A., Oliva M.E., Dukart G., et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 61 (2008) 329-338
89. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., et al. Bad bugs, no drugs: no ESKAPE!. An update from the Infectious Diseases Society of America. Clin Infect Dis 48 (2009) 1-12
90. Florescu I., Beuran M., Dimov R., Razbadauskas A., Bochan M., Fichev G., et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 62 Suppl 1 (2008) i17-i28
91. Vasilev K., Reshedko G., Orasan R., Sanchez M., Teras J., Babinchak T., et al. A phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 62 Suppl 1 (2008) i29-i40
92. Chemlay R.F., Hanmod S., Mulanovich V., Adachi J., Rolston K., Raad I., et al. Tigecycline usage in cancer patients with serious infections: a report on 110 cases from a single institution. [abstract K-1413]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting; Washington, DC (2008)
93. Li J., Nation R.L., Turnidge J.D., Milne R.W., Coulthard K., Rayner C.R., et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 6 (2006) 589-601
94. Michalopoulos A., and Falagas M.E. Colistin and polymyxin B in critical care. Crit Care Clin 24 (2008) 377-391
95. Evans M.E., Feola D.J., and Rapp R.P. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 33 (1999) 960-967
96. http://clinicaltrials. gov/ct2/results?term=colistin
97. Kallel H., Hergafi L., Bahloul M., Hakim A., Dammak H., Chelly H., et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intens Care Med 33 (2007) 1162-1167
98. Rios F.G., Luna C.M., Maskin B., Saenz Valiente A., Lloria M., Gando S., et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur Respir J 30 (2007) 307-313
99. Hachem R.Y., Chemaly R.F., Ahmar C.A., Jiang Y., Boktour M.R., Rjaili G.A., et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother 51 (2007) 1905-1911
100. Garnacho-Montero J., Ortiz-Leyba C., Jimenez-Jimenez F.J., Barrero-Almodovar A.E., Garcia-Garmendia J.L., Bernabeu-Wittel I.M., et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36 (2003) 1111-1118
101. Reina R., Estenssoro E., Saenz G., Canales H.S., Gonzalvo R., Vidal G., et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intens Care Med 31 (2005) 1058-1065
102. Michalopoulos A., Fotakis D., Virtzili S., Vletsas C., Raftopoulou S., Mastora Z., et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant gram-negative bacteria: a prospective study. Respir Med 102 (2008) 407-412
103. Levin A.S., Barone A.A., Penco J., Santos M.V., Marinho I.S., Arruda E.A., et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 28 (1999) 1008-1011
104. Linden P.K., Kusne S., Coley K., Fontes P., Kramer D.J., and Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 37 (2003) e154-e160
105. Markou N., Apostolakos H., Koumoudiou C., Athanasiou M., Koutsoukou A., Alamanos I., et al. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit Care (London, England) 7 (2003) R78-R83
106. Michalopoulos A.S., Tsiodras S., Rellos K., Mentzelopoulos S., and Falagas M.E. Colistin treatment in patients with ICU-acquired infections caused by multiresistant gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 11 (2005) 115-121
107. Falagas M.E., Rizos M., Bliziotis I.A., Rellos K., Kasiakou S.K., and Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 5 (2005) 1
108. Landman D., Georgescu C., Martin D.A., and Quale J. Polymyxins revisited. Clin Microbiol Rev 21 (2008) 449-465
109. Song J.Y., Cheong H.J., Lee J., Sung A.K., and Kim W.J. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. Intern J Antimicrob Agents 33 (2009) 33-39
110. Petrosillo N., Ioannidou E., and Falagas M.E. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 14 (2008) 816-827
111. Craig W.A., and Ebert S.C. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 36 (1992) 2577-2583
112. Nicolau D.P. Pharmacodynamic optimization of beta-lactams in the patient care setting. Crit Care (London, England) 12 Suppl 4 (2008) S2
113. Mouton J.W., and Vinks A.A. Continuous infusion of beta-lactams. Curr Opin Crit Care 13 (2007) 598-606
114. Kasiakou S.K., Sermaides G.J., Michalopoulos A., Soteriades E.S., and Falagas M.E. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 5 (2005) 581-589
115. Bodey G.P., Ketchel S.J., and Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 67 (1979) 608-616
116. Lodise Jr. T.P., Lomaestro B., and Drusano G.L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 44 (2007) 357-363